A significant difference in stromal p16 expression levels between type I and II endometrial carcinomas raises the possibility that the aggressive oncogenic behavior of type II lesions may be associated with p16 overexpression in the peritumoral stroma. The gene discussed is CDKN2A; the disease is endometrial carcinoma.